NICE guidance on bevacizumab in combination with gemcitabine and carboplatin for treating the first recurrence of platinum-sensitive advanced ovarian cancer. [electronic resource]
Producer: 20130909Description: 691-2 p. digitalISSN:- 1474-5488
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- economics
- Bevacizumab
- Carboplatin -- administration & dosage
- Cost-Benefit Analysis
- Deoxycytidine -- administration & dosage
- Drug Costs
- Female
- Humans
- Neoplasm Recurrence, Local -- drug therapy
- Ovarian Neoplasms -- drug therapy
- Practice Guidelines as Topic
- Quality-Adjusted Life Years
- Survival Analysis
- Time Factors
- Treatment Outcome
- Gemcitabine
No physical items for this record
Publication Type: News
There are no comments on this title.
Log in to your account to post a comment.